|130th MAINE LEGISLATURE|
|LD 1117||LR 1071(02)|
|An Act To Prevent Excessive Prices for Prescription Drugs|
|Fiscal Note for Bill as Amended by Committee Amendment " "|
|Committee: Health Coverage, Insurance and Financial Services|
|Fiscal Note Required: Yes|
|Current biennium revenue increase - General Fund
Minor cost increase - Other Special Revenue Funds
Minor revenue increase - Other Special Revenue Funds
|Correctional and Judicial Impact Statements|
|This bill may
increase the number of civil suits filed in the court system.
The additional workload associated with the minimal number of new cases filed in the court system does not require additional funding at this time.
The collection of additional filing fees may increase General Fund and other dedicated revenue by minor amounts.
|Fiscal Detail and Notes|
|Upon an action brought by the Office of the Attorney General (OAG) in Superior Court, a civil penalty of $500,000 may be assessed against any prescriptin drug manufacturer for certain violations. It is anticipated that the new and increased penalty will increase revenues to the General Fund and will depend on the number of violations.|
|Any additional costs to the OAG and the Maine Health Data Organization are expected to be minor and can be absorbed within existing budgeted resources.|